Recon Regulatory Catalyst OrthoScience Receives FDA 510(k) Clearance for Expanded Indications of the Fracture Shoulder System byJosh SandbergDecember 3, 2025
Financial Recon Catalyst OrthoScience Secures $15.0 Million in Growth Financing byTim AllenOctober 22, 2025
Recon Top Stories Catalyst OrthoScience Announces Full Commercial Release of Fracture Shoulder System byJosh SandbergAugust 13, 2025
Recon Top Stories Catalyst OrthoScience Announces 5-8 Year Data Reporting Significant Functional Improvement and Pain Reduction for Anatomic Total Shoulder Arthroplasty byTim AllenJune 4, 2025
Recon Catalyst OrthoScience Announces Leadership Transition: Miguel A. Ramirez, MD, Appointed Chief Medical Officer byJosh SandbergApril 2, 2025
Recon Regulatory Top Stories Catalyst OrthoScience Announces FDA 510(k) Clearance for Shoulder Fracture System and First Cases byJosh SandbergOctober 15, 2024
Financial Recon Top Stories Catalyst OrthoScience Surpasses 10,000 Total Shoulder Arthroplasty (TSA) Procedures and Announces $20 Million Financing byJosh SandbergSeptember 10, 2024
Extremities Catalyst OrthoScience Announces Amy Ables, Ph.D. as Chief Strategy Officer byJosh SandbergNovember 20, 2023
Recon Top Stories Catalyst OrthoScience Announces First Series of Procedures Using World’s Only Fully Convertible Stemmed CSR TSA System Featuring an Ellipsoid Humeral Head byJosh SandbergMay 25, 2023
Recon Research Published in JSES Indicates that the Catalyst™ CSR Total Shoulder System Outperforms Traditional Stemmed Implants byJosh SandbergMarch 6, 2023
